Alterity Therapeutics annual stock-based compensation
2021
2022
2023
2024
2025
Alterity Therapeutics Stock-Based Compensation Growth & History (ATHE)
Alterity Therapeutics's stock-based compensation was $979,920 for fiscal 2025.
View full Alterity Therapeutics company overviewAlterity Therapeutics annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-06-30 | $979,920 | $97,970 | +11.11% |
| 2024 | 2024-06-30 | $881,950 | −$101,771 | −10.35% |
| 2023 | 2023-06-30 | $983,721 | −$522,400 | −34.69% |
| 2022 | 2022-06-30 | $1.5M | −$444,442 | −22.79% |
| 2021 | 2021-06-30 | $2.0M | — | — |
Alterity Therapeutics stock-based compensation trends
Between the periods ended 2021-06-30 and 2025-06-30, Alterity Therapeutics's stock-based compensation decreased from $2.0M to $979,920, a change of −$970,643.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Alterity Therapeutics source filings ↗